“It is with my full support that we make this change of the Chairmanship of Scandion Oncology. Peter Høngaard brings a vast experience in building and running life sciences companies that we can benefit greatly from in Scandion Oncology. I am proud of where we have taken Scandion Oncology from the start to its current position. Now the journey through Phase II clinical studies and commercialization begins and I look forward to this journey together with the rest of the Board.” says Jørgen Bardenfleth.
Peter Høngaard comments: "It is a pleasure for me to accept the role as chairman of Scandion Oncology. Cancer is one of the biggest disease burdens in modern society and with the technology developed by Scandion Oncology patient treatment outcomes can be significantly improved. I can see the company is on track to deliver results on the first part of the Phase 2 study in first half of 2020 and it’s a pleasure to be part of this exciting journey."
"I am very pleased to have Peter Høngaard as the new Chairman of the Board of Scandion Oncology. I have known Peter for several years and he has extensive experience within Biotech and Pharma. I feel confident that his expertise will take Scandion Oncology to the next level. I also want to take this opportunity to thank Jørgen Bardenfleth, who has done a terrific job as Chairman. He has with great success lead Scandion Oncology through its first two years including the IPO and recent rights issue." CEO Nils Brünner states.
For further information regarding Scandion Oncology, please contact:
Nils Brünner, CEO
Phone: +45 26 14 47 08
E-mail: nb@scandiononcology.com
This information is information that Scandion Oncology is obliged to publish in accordance to the EU Market Abuse Regulation. The information was provided by the contact person above for publication on October 1, 2019.
Scandion Oncology A/S is a biotechnology company founded in 2017 for the purpose of addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of cancer which contains drug resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro-studies SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company’s leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now ready to initiate clinical phase II trials with its lead compound, SCO-101 in patients with drug resistant cancer. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018.